BRAHMS copeptin assay regulatory update

The U.K.'s NICE issued final guidance on Thermo Fisher's BRAHMS copeptin assay in combination with cardiac troponin testing to rule out myocardial infarction (MI) in patients presenting with acute chest pain. The agency said additional trials of the assay are needed to support adoption of the BRAHMS assay on the NHS, but noted that it was not recommending against use of the assay. The guidance is in line with a March preliminary appraisal (see BioCentury, March 21). ...